Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.29 - $14.14
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$3.08M
Enterprise Value-$3.69M
Total Cash (Recent Filing)$3.93M
Total Debt (Recent Filing)$26.00K
Price to Earnings (P/E)―
Beta2.97
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding6,259,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit167.56
Enterprise Value/Ebitda0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress (IDE Filing)Filing an IDE is a structural milestone: it permits U.S. clinical data collection necessary for future regulatory approvals and commercialization. Over months this moves the company from preclinical work toward pivotal trials, improving its ability to partner, license, or attract investor funding tied to clinical progress.
Validated Preclinical And Early Clinical DataRobust peer‑reviewed preclinical results and favorable early human metrics provide durable scientific credibility. This external validation reduces technical and regulatory risk, strengthens clinician and partner confidence, and supports differentiation for a long‑life implantable CGM in a competitive market.
Low Absolute Debt And Recent Debt ReductionLow nominal leverage and a debt‑for‑equity swap meaningfully lower near‑term creditor pressure and interest obligations. Structurally this modestly improves solvency metrics and extends runway versus carrying that debt, reducing immediate default risk while funding needs persist.
Bears Say
No Commercial RevenueThe company lacks a commercial revenue base, so it cannot internally fund development or scale. Persistent operating losses force continuous external financing, increasing dilution and constraining strategic options; this undermines long‑term viability until revenue generation occurs.
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow of ~-$16M TTM creates ongoing funding pressure. Over 2–6 months this elevates dilution or refinancing risk, limits ability to execute clinical programs, and forces management to prioritize short‑term financing over longer‑term commercial investments.
Nasdaq Deficiency Notices And Negative EquityActive Nasdaq deficiency letters and sub‑threshold stockholders' equity create structural listing and capital‑access risk. Potential delisting would materially impair liquidity, raise cost of capital, and could force accelerated or dilutive financings or restructuring, hindering strategic execution.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.29 and its highest was $14.14 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $3.08M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is Aug 13, 2026 which is in 25 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on May 14, 2026. The company reported -$2.646 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.646.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 6,259,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$2.646 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.84%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.
Technical Analysis
Ownership Overview
0.18% Insiders
0.18% Mutual Funds
0.80% Other Institutional Investors
98.85% Public Companies and
Individual Investors